-
Efficacy and safety of itacitinib versus placebo combined with corticosteroids in the treatment of acute graft-versus-host disease (GRAVITAS-301)
Time of Update: 2022-03-09
>>>Study Results Research Process and Baseline The GRAVITAS-301 trial enrolled 439 eligible patients between July 19, 2017, and October 3, 2019, who were randomly assigned to itacitinib (N=219) or placebo group (N=220) (see Figure 1 for details) .
-
Guide Interpretation·Professors Shen Zhixiang, Qiu Lugui, Zhang Qingyuan, and Xu Wei at the Roundtable: Pay attention to the "CSCO Guidelines for Raising Whiteness v2021" to reduce the risk of hematological tumor agranulocytosis and fever
Time of Update: 2022-03-08
Zhixiang Shen emphasized that clinicians should rationally apply G-CSF under the guidance of the "CSCO Whitening Guidelines v2021" to reduce the risk of FN and avoid the death of patients due to serious infection during treatment, and should not be overly concerned about the second tumor .
-
Efficacy and safety of belintuumab in children with relapsed/refractory acute B lymphocytic leukemia
Time of Update: 2022-03-08
Children who achieve a second CR have a 5-year disease-free survival rate of 40% to 50%, depending on the patient's risk stratification .
-
Case report: Daratumumab in immune thrombotic thrombocytopenic purpura
Time of Update: 2022-03-08
Patient 1 initially achieved complete clinical remission and restoration of ADAMTS13 enzyme activity with standard therapy, followed by relapse and eventual development of persistent autoantibodies against ADAMTS13 enzyme despite treatment with rituximab .
-
Study discovers new target for the treatment of malignant hematological tumors
Time of Update: 2022-03-08
In this work, the researchers found through high-throughput screening that two compounds with similar structures, P22077 and 1247825-37-1, can selectively inhibit the proliferation of EZH2-Y641C mutant AML cell lines and selectively degrade the EZH2-Y641C protein.
-
Precision therapy for leukemia!
Time of Update: 2022-03-08
▎WuXi AppTec content team editor Recently, an IDH1 inhibitor, Avonib tablets (trade name: Tosuwo®), has been approved by the China National Medical Products Administration (NMPA) for marketing, and the indication is "for Treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) harboring an IDH1 susceptibility mutation" .
-
Nat Cell Biol Zhu Xiaofan/Gu Jin/Cheng Tao team collaboration revealed the essence of leukemia minimal residual disease for the first time
Time of Update: 2022-03-08
By comparing the single-cell transcriptome data of leukemia cells in three stages of initial diagnosis, D19 and relapse, the authors found that the differentiation stage of residual leukemia cells has no significant characteristics, but the cell cycle is more in a quiescent state, and the hypoxia signaling pathway is significantly activated .
-
Big coffee explores "Austria" Professor Zhao Yu: Innovation and breakthroughs are emerging, Otuzumab explores the future road of relapsed, refractory
Time of Update: 2022-03-08
In this regard, Yimaitong specially contacted Professor Zhao Yu of the First Medical Center of the Chinese People's Liberation Army General Hospital to discuss the application prospect of otuzumab in a variety of patients with relapsed and refractory indolent lymphoma including FL .
-
Persistent MRD negativity and the use of daratumumab in patients with NDMM: analysis of data from the MAIA and ALCYONE studies
Time of Update: 2022-03-08
Two phase III studies (MAIA and ALCYONE) evaluated the efficacy of daratumumab-based regimens in patients with NDMM who were not candidates for hematopoietic stem cell transplantation and showed that daratumumab-based regimens compared with conventional regimens Monoclonal antibody therapy allows NDMM patients to achieve higher MRD-negative rates and longer PFS .
-
A picture to understand how proteasome inhibitors work in multiple myeloma?
Time of Update: 2022-03-08
RECOMMEND RECOMMENDED READING 1.
2021 ASH is very interesting | US MM-6 study results updated on continuous treatment of multiple myeloma!
Click "read the original text", let's make progress together
-
Professor Huang Xiaojun led a national multi-center prospective study to reveal the long-term follow-up efficacy of haploidentical hematopoietic stem cell transplantation in the treatment of severe aplastic anemia Sci. Bull.
Time of Update: 2022-03-07
Recently, the team of Professor Xiaojun Huang from the Institute of Hematology of Peking University published a research paper entitled "Long-term follow-up of haploidentical transplantation in relapsed/refractory severe aplastic anemia: a multicenter prospective study" in Science Bulletin.
-
The child with severe anemia turned out to be "phagocytosing blood"
Time of Update: 2022-03-07
At this time, it was clinically highly suspected that Xiao Ming's anemia was caused by pulmonary hemorrhage .
The electronic bronchoscopy opinion: pulmonary hemorrhage; the results of the postoperative alveolar lavage fluid cytology test report: a large number of hemosiderin cells can be seen .
-
Adaptive Treatment of Follicular Lymphoma: Stepping into the Threshold of Precision Therapy
Time of Update: 2022-03-07
The study was designed with a control group in which all patients with a good response (partial metabolic remission or CMR), regardless of MRD status, received standard rituximab maintenance therapy every 2 months for 2 years .
-
Mechanism, examination methods and prevention strategies of allergic blood transfusion reaction caused by platelet transfusion
Time of Update: 2022-03-07
X. Click "Read the original text", let's make progress together: transfusion reactions in haptoglobin-deficient patients.
Kennedy, LAD, Case, LD, Hurd, DD, Cruz, JM, Pomper, GJ: A prospective, randomized, double-blind controlled trial of acetaminophen and diphenhydraminepretransfusion medication versus placebo for the prevention of transfusion reactions.
-
FDA approves Pyrukynd for hemolytic anemia in adults
Time of Update: 2022-03-05
The FDA on Thursday approved Agios Pharmaceuticals' Pyrukynd (mitapivat) for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency, regardless of transfusion status .
-
NEJM: LentiGlobin Gene Therapy for Sickle Cell Disease
Time of Update: 2022-03-05
Cohort C was established for the pivotal assessment of LentiGlobin in sickle cell disease with stricter inclusion criteria requiring at least 4 serious vascular occlusive events in the 24 months prior to enrollment .
-
Ann Hematol: Comparison of the efficacy of 19 drug therapies in patients with idiopathic thrombocytopenic purpura
Time of Update: 2022-03-05
For example, regimen M: eltrombopag plus rituximab, it has a more than 90% chance of being number one, so this regimen is probably the most effective of the 19 regimensThe inferred endpoints used were not necessarily the same between studies, which was the main source of heterogeneity in this meta-analysis .
-
AJH: Single-dose versus low-dose rituximab for corticosteroid-resistant or recurrent ITP: a multicenter, randomized, controlled study
Time of Update: 2022-03-05
Researchers conducted a prospective, multicenter, open-label, randomized controlled trial to compare the efficacy and safety of RTX in two different dose regimens in patients with corticosteroid-resistant or recurrent ITPFigure 1: Study Design and Treatment Disposition .
-
AJH: Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab - patient-reported results from the APOLLO trial
Time of Update: 2022-03-05
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial .
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial .
-
Clin Exp Med: Changes in Platelet Activity and Turnover Index During Immune Thrombocytopenia Treatment Response
Time of Update: 2022-03-05
No significant differences in plasma sCD40L (c), MPV (d), GC (e) or GC index (f) levelsFigure 2: Comparison of platelet count, platelet activity, and turnover markers in ITP at newly diagnosed versus refractory disease .
